New therapeutic approaches in type 2 diabetes

Acta Clinica Belgica

Volumn 63, Issue 6, 2008, Pages 402-407

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Exenatide; Incretins; Insulin analogues; Oral anti diabetic agents; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN DERIVATIVE; INSULIN SECRETAGOGUE; INSULIN SENSITIZING AGENT; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SAXAGLIPTIN; SHORT ACTING DRUG; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ANXIETY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIARRHEA; DIET THERAPY; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; SIDE EFFECT; WEIGHT GAIN;

EID: 57849133538     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2008.083     Document Type: Conference Paper

References (30)

1. Scheen AJ. Pathophysiology of type 2 diabetes. Acta Clin Belg 2003; 58: 335-41.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-46.
3. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31 (Suppl 1): S12-S54.
4. Nathan DM, Buse JB, Davidson MB, et al. - Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008, 31, Oct 22. [Epub ahead of print].
5. Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998; 55: 225-36.
6. Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
7. Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003; 63: 1165-84.
8. Scheen AJ. Treatment of type 2 diabetes. Acta Clin Belg 2003; 58: 318-24.
9. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997; 54: 355-68.
10. Scheen AJ, Radermecker RP, Philips JC, et al. Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège 2007; 62 (numéro spécial Synthèse) : 40-6.
11. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-40.
12. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-30.
13. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
14. Ruige JR. Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus. Acta Clin Belg 2008; 63: 81-5.
15. Scheen AJ, Radermecker RP, Philips JC, Paquot N. Les incré tinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse 2007; 3: 1884-8.
16. Idris S, Donnelly R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diab Obes Metab 2007; 9: 153-65.
17. Lyseng-Williamson KA. Sitagliptin. Drugs 2007; 67: 587-97.
18. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67: 935-54.
19. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol 2008; 158: 773-84.
20. Drucker DJ, Buse JB, Taylor K, et al, for the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes. Lancet 2008; 372: 1240-50.
21. VilsbØll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007; 16: 231-7.
22. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2008 Sept 25. [Epub ahead of print].
23. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
24. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
25. Scheen AJ. The endocannabinoid system : a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2009; 10: 56-74.
26. Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New Engl J Med 2006; 355: 2427-43.
27. Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 2005; 366: 1279-89.
28. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
29. Scheen AJ, Finer N, Hollander P, et al for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
30. Scheen AJ. Exenatide once weekly in type 2 diabetes (comment). Lancet 2008; 372: 1197-8.